Single nanoparticle analysis-based CRISPR/Cas12 bioassay for amplification-free HIV detection

Area of Science:

• Biotechnology
• Molecular Diagnostics
• CRISPR Technology

Background:

• Traditional HIV detection methods often rely on signal amplification, increasing the "window period" before diagnosis.
• Amplification strategies can introduce challenges such as primer interference and false positives.
• There is a need for sensitive and specific HIV detection methods with reduced turnaround times.

Purpose of the Study:

• To develop an amplification-free bioassay for HIV detection.
• To leverage CRISPR's cleavage activity and single-nanoparticle analysis for enhanced sensitivity.
• To overcome the limitations of existing HIV diagnostic techniques.

Main Methods:

• Developed a novel bioassay utilizing CRISPR-Cas gene editing system's cleavage activity.
• Integrated single-nanoparticle analysis for sensitive signal detection.
• The assay was designed to be amplification-free, avoiding primer interference and false positives.

Main Results:

• Achieved an attomolar detection limit for HIV.
• Demonstrated adequate selectivity, distinguishing HIV from other targets.
• Validated the bioassay's accuracy and sensitivity in serum and cell samples.

Conclusions:

• The developed amplification-free bioassay offers a sensitive and accurate method for HIV detection.
• This approach effectively reduces the "window period" for HIV diagnosis.
• CRISPR and single-nanoparticle technology show promise for next-generation diagnostics.